News & Publications

Jennifer N. Clements, PharmD, BCPS, CDE, BCACP

Jennifer N. Clements

Jennifer N. Clements, PharmD, BCPS, CDE, BCACP, is Associate Professor of Pharmacy Practice at Presbyterian College School of Pharmacy in Clinton, South Carolina.

Dr. Clements earned her Doctor of Pharmacy degree from Campbell University and completed a primary care pharmacy practice residency at the Ralph H. Johnson VA Medical Center (VAMC) in Charleston, South Carolina. She is a board-certified pharmacotherapy specialist, board-certified ambulatory care pharmacist, and certified diabetes educator.

Upon completion of her residency, Dr. Clements joined the faculty at the Bernard J. Dunn School of Pharmacy, Shenandoah University in Winchester, Virginia. She developed and practiced in the pharmacotherapy clinic, at the Martinsburg VAMC in Martinsburg, West Virginia. Since joining the faculty of Presbyterian College School of Pharmacy, she developed a clinical practice site delivering chronic disease state management services at Laurens Family Medicine in Laurens, South Carolina. At Laurens Family Medicine, Dr. Clements collaborates with two physician assistants, three nurse practitioners, and four medical physicians.

Dr. Clements is a member of American Association of Colleges of Pharmacy (AACP), American Association of Diabetes Educators (AADE), American College of Clinical Pharmacy (ACCP), and American Society of Health-System Pharmacists (ASHP). She is the current President-Elect for the South Carolina Society of Health-System Pharmacists (SCSHP) and is serving a three-year term on the Board of Directors for this state organization.

With expertise in ambulatory care, Dr. Clements often lectures on the topics of diabetes and obesity management. She has authored numerous journal articles and book chapters, and she regularly writes for AADE and maintains the Weight Management resource page for iForumRx.

Dr. Clements enjoys reading, cooking, and spending quality time with family – Matt (husband), Reagan (daughter), Joseph (son) and three animals.


Recent Posts:

  • Lorcaserin and Cardiovascular Outcomes

    By Jennifer N. Clements, PharmD, BCPS, CDE, BCACP | Oct 16, 2018

    GettyImages-467671852_850x420
    Jennifer Clements loves discussing obesity management in and out of her clinical practice. In this blog, she discusses the findings of a study looking at the cardiovascular safety of the anti-obesity medication lorcaserin.

  • 4 Tips for Staying Current on Literature

    By Jennifer N. Clements, PharmD, BCPS, CDE, BCACP | Sep 06, 2018

    Reading-850px
    There is so much information about diabetes published on a daily, even weekly basis, that reviewing and digesting it for clinical application can become overwhelming. You may have access to a wealth of information, but how do you keep up with it in a way that makes sense for your own practice? Jennifer Clements shares her 4 tips for staying current on diabetes literature.

  • 3 Reasons to be Excited for AADE18

    By Jennifer N. Clements, PharmD, BCPS, CDE, BCACP | Aug 01, 2018

    AADE18_Reg-open_850
    Jennifer Clements won't be able to attend the AADE's annual conference this year, but she's excited for all the individuals and colleagues who will make it. Read the highlights all attendees should be getting excited about here.

  • The 2018 American Diabetes Association – What a Quick Ride

    By Jennifer N. Clements, PharmD, BCPS, CDE, BCACP | Jul 03, 2018

    Conference presentation
    Jennifer Clements had the opportunity to attend and present at the American Diabetes Association's Scientific Sessions conference last week. Read about the highlights of her experience, and share yours in the comments if you have any.

  • New SGLT-2 Inhibitor – Ertugliflozin (STEGLATRO)

    By Jennifer N. Clements, PharmD, BCPS, CDE, BCACP | May 01, 2018

    ThinkstockPhotos-97429646_850x420
    When Associate Professor Jennifer Clements updates course materials for her students, she learns about new diabetes management medications herself. Here she shares an overview of a recently FDA-approved SGLT-2 inhibitor.

In This Section

News & Publications